Core Viewpoint - The company reported a revenue of 302 million yuan for the first half of 2025, reflecting a year-on-year growth of 29.33%. However, it also recorded a net loss of 11.15 million yuan, a decline of 117.88% compared to the previous period. The company has decided not to distribute cash dividends, issue bonus shares, or increase capital from reserves [1]. Financial Performance - Revenue for the first half of 2025 reached 302 million yuan, marking a 29.33% increase year-on-year [1]. - The net profit showed a loss of 11.15 million yuan, which is a significant decline of 117.88% [1]. Dividend Policy - The company announced that it will not distribute cash dividends, issue bonus shares, or utilize reserves for capital increase [1].
共同药业：2025年上半年净利润亏损1115.25万元，下降117.88%